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1. Introduction 
Ghrelin is a 28 amino acid peptide hormone derived from the X/A like endocrine cells located 
in the gastric mucosa. Since its discovery more than a decade ago, about 5000 papers have 
been reported. The scope of these reports is broad and ranges from the gene structure, 
transcriptional regulation, posttranslation modification, ligand-receptor binding activities, 
intracellular signaling, to various biological functions such as food intake, energy balance, 
glucose and lipid metabolism, cardiovascular disease and immunomodulation. In this chapter, 
we will summarize the advance of our knowledge on this fascinating hormone, ghrelin. 
2. The history of ghrelin discovery 
2.1 Development of GHS (growth hormone secretagogues) 
Growth hormone (GH) was first identified for its effect on longitudinal growth. Recombinant 
growth hormone is therefore used as the treatment for individuals with short stature in 
various conditions (Chipman, 1993; Jorgensen & Christiansen, 1993). However, GH 
replacement therapy encounters several drawbacks such as low bioavailability and side effects 
upon its administration. Moreover, most growth hormone-deficient individuals exhibit a 
secretory defect rather than a primary deficiency in the production of growth hormone.  
A synthetic hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP-6), was identified as a 
potent stimulator on GH release in vitro and in vivo by an unknown mechanism (Bowers et 
al., 1984). Because of its poor oral bioavailability and short half-life in human serum, GHRP-
6 was selected only as a structural model to design non-peptide mimetics (Bowers et al., 
1992). However, as a peptide, GHRP-6 did not readily lend itself to optimization of 
pharmacokinetic properties by medicinal chemistry. The benzodiazepine like template 
containing aromatic substitution was therefore discovered as potential non-peptide 
structure to model the GHRP-6 structure (Bowers et al., 1980). Based on the structure-
activity relation, a non-peptidyl GH secretagogue L-692, 429, was identified. This non-
peptidyl GH secretagogue synergizes with GHRP-6 to stimulate GH release and cAMP 
production (Smith et al., 1993).  
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In parallel with developing structure activity relationships for the benzolactams, alternative 
approach was proposed. It has been suggested that the derivatives of frequently occurring 
units was used as a useful approach to design receptor agonists and antagonists (Evans et 
al., 1988). These recurring structural units were termed “privileged structures” and had been 
recognized (Patchett et al., 1995) as hydrophobic double ring systems contributing to 
receptor binding of many antagonists of biogenic amines. By replacing d-Trp by O-benzyl-d-
serine and incorporating a methanesulfonyl amido group, a new drug with excellent oral 
bioavailability and specificity in its release of GH without significant effect on plasma levels 
of other hormones was discovered and named L-163,191 (MK-0677) (Patchett et al., 1995). 
2.2 Discovery of GHS-R 
Extensive researches had been focused on the regulation of GH secretion in the 90s, due to 
its potential in the therapeutics of GH deficient related diseases. GH secretion is mainly 
regulated by GH-releasing hormone (GHRH) (Frohman & Jansson, 1986) and somatostatin 
(Katakami et al., 1986, which are stimulatory and inhibitory hormones respectively. Studies 
on GHS synthetic peptides and non-peptides which stimulate GH release indicated a 
distinct third pathway in addition to GHRH and somatostatin and the presence of a unique 
receptor (Bowers et al., 1984). Their activity was not blocked by the opiate receptor 
antagonist naloxone. Furthermore, these molecules were neither GHRH receptor agonists 
nor somatostatin receptor antagonists (Cheng et al., 1989; Blake & Smith, 1991; Cheng et al., 
1991). This novel receptor was identified in porcine and rat anterior pituitary membranes 
using MK-0677 as a ligand. The binding of this receptor is Mg2+-dependent and could be 
inhibited by GTP-gamma-S, indicating that it is a G-protein-coupled receptor (GPCR) (Pong 
et al., 1996). Activation of this GPCR by GHS results in the stimulation and amplified 
pulsatile release of growth hormone, and it was therefore named as GHS-R. This GHS-R 
defines a novel neuroendocrine pathway for the control of pulsatile GH release. The full-
length sequence of this receptor was identified by using the expression-cloning strategy in 
Xenopus oocytes. Activation of GHS-R induces a transient increase in the concentration of 
intracellular calcium in somatotrophs (Bresson-Bepoldin & Dufy-Barbe, 1994), the increase 
in the level of inositol trisphosphate (IP3) (Mau et al., 1995) and activity of protein kinase-C 
(PKC) (Cheng et al., 1991). 
2.3 Identification of ghrelin 
Cloning of the GHS-R cDNA allows the engineering of cell lines stably expressing the GHS-
R, which are essential for identification of endogenous GHS-R ligands. Through a process of 
reverse pharmacology, the endogenous nature ligand for GHS-R1a was identified from the 
gastric extracts and named as ghrelin. By detecting the intracellular calcium concentration in 
CHO cells expressing GHS-R1a as a functional readout, Kojima et al. screened several tissue 
extracts from brain, lung, heart, kidney, stomach and intestine, and unexpectedly 
discovered the active agonist for the GHS-R1a in the stomach rather than in the brain 
(Kojima et al., 1999). The active component was purified by successive chromatography 
including gel filtration, ion-exchange high-performance liquid chromatography (HPLC) and 
reverse-phase HPLC (RP-HPLC) (Kojima et al., 1999). Its amino acid sequence in rat was 
finally determined as GSSFLSPEHQKAQQRKESKKPPAKLQPR in which the serine-3 (Ser3) 
is n-octanoylated. This octanoylation is necessary for its binding and activation of the GHS-
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R. This 28 amino acid peptide was named ghrelin based on the word root “ghre” in proto-
indo-european language for “growth” to depict its ability of stimulating the release of 
growth hormone (Kojima et al., 1999). Ghrelin is the only known peptide modified by a fatty 
acid, and it shares no structure homology with growth hormone secretagogues. Human 
ghrelin was cloned using the primers based on rat ghrelin cDNA under low stringency 
condition. Only two amino acids are different between human and rat preproghrelin 
(Kojima et al., 1999), indicating that ghrelin is highly conserved between species. 
3. The gene structure of ghrelin 
3.1 Ghrelin gene 
Localized on the chromosome 3p25–26, the human ghrelin gene comprises five exons, same 
as the mouse gene (Tanaka et al., 2001a; Kanamoto et al., 2004). The short first exon contains 
only 20 base pairs, which encode part of the 5’-untranslated region. There are two different 
transcriptional initiation sites in the ghrelin gene; one occurs at -80 and the other at -555 
relative to the ATG initiation codon, resulting in two distinct mRNA transcripts (transcript-
A and transcript-B) (Kanamoto et al., 2004). 
The 5’-flanking region of the human ghrelin gene contains a TATA box-like sequence 
(TATATAA; -585 to -579), as well as putative binding sites for several transcription factors 
such as AP2, basic helix-loop-helix (bHLH), hepatocyte nuclear factor-5, NF-κB, and half-
sites for estrogen and glucocorticoid response elements (Tanaka et al., 2001a; Kishimoto et 
al., 2003; Kanamoto et al., 2004). Neither a typical GC nor a CAAT box was found. 
3.2 Ghrelin gene-derived transcripts 
The 28 amino acids of the functional ghrelin peptide are encoded by ghrelin gene which 
consists of 4 introns and 5 exons, including a non-coded exon 1. In rat, mouse and pig, the 
codon for Gln14 (CAG) is used as an alternative splicing signal to create two different ghrelin 
mRNAs (Hosoda et al., 2000b). One encodes the ghrelin precursor, and another encodes des-
Gln14-ghrelin precursor: a spliced variant without the codon for glutamine in position 14 
(pre-pro-des-Gln14- ghrelin mRNA) (Hosoda et al., 2003). Des-Gln14-ghrelin is identical to 
ghrelin, except for the deletion of Gln14. Nearly all of the cDNA clones isolated from human 
stomach encodes the pre-pro-ghrelin mRNA, only a few cDNA clones encodes the pre-pro-
des-Gln14-ghrelin mRNA (Hosoda et al., 2003).  
Another splicing variant was detected in the mouse testis (Tanaka et al., 2001b). This variant, 
a ghrelin gene-derived transcript (GGDT), comprises the 68-bp 5’-unique sequence located 
between exons 3 and 4 of the ghrelin gene, and the remaining 252 bp sequence identical to 
the exons 4 and 5 of mouse ghrelin gene. GGDT encodes a 54 amino acid peptide consisting 
of 12 amino acid residues which is unrelated to the ghrelin gene and the COOH-terminal 42-
amino acid sequence of mouse ghrelin precursor. The function of this variant is not clear. 
In addition, a human exon 3-deleted mRNA transcript has been described in breast and 
prostate cancer (Yeh et al., 2005). The murine homologue (exon 4-deleted mRNA transcript) 
has also been identified in comprehensive murine tissues (Jeffery et al., 2005). Theses 
variants are likely products of the ghrelin gene attributed to alternative splicing 
mechanisms. 
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4. Posttranslational modification of ghrelin 
In vitro and in vivo studies have demonstrated that the prohormone convertase 1/3 (PC1/3) 
is the only identified enzyme responsible for processing of proghrelin into ghrelin (Zhu et 
al., 2006). This endoprotease co-localizes with ghrelin in gastric endocrine cells and 
processes the 94 amino acids human ghrelin precursor into the 28 amino acids mature 
ghrelin through limited proteolytic cleavage (Ozawa et al., 2007). 
Octanoylation of the third amino acid Serine is the most unique posttranslational 
modification of ghrelin. Ghrelin is the only protein currently known to be octanoylated. 
This octanoylation is essential for binding of ghrelin with its receptor, GHS-R1a. The 
enzyme that catalyzes the octanoylation of ghrelin was identified by two individual study 
groups and designated as ghrelin O-acyltransferase (GOAT) in 2008 (Gutierrez et al., 2008; 
Yang et al., 2008a). GOAT is a member of the family membrane-bound O-acyltransferases, 
with its structure conserved among different species. Transcripts for both GOAT and 
ghrelin are present predominantly in stomach and pancreas. Genetic disruption of the 
GOAT gene in mice leads to complete absence of octanoylated ghrelin in circulation. The 
design of GOAT inhibitors may therefore provide a new approach for the treatment of 
obesity and diabetes. In vitro study has demonstrated that GOAT activity could be 
significantly inhibited by an octanoylated ghrelin pentapeptide and other end-products 
(Yang et al., 2008b), suggesting the existence of a negative feedback regulation. In 
addition to the octanoylation, different acylation by other fatty acid has been reported. 
Studies have revealed some naturally occurring variants of ghrelin such as decanoyl 
ghrelin based on the different acylation on the serine-3 residue, which exhibit 
physiological function similar to octanoylated ghrelin (Ghigo et al., 2005). 
In addition, ghrelin has been reported to be phosphorylated by protein kinase C ǂ, ǃ, and ǅ 
at serine-18 residue which affects the secondary structure and membrane binding property 
of ghrelin (Dehlin et al., 2008). The intracellular function of phosphorylated ghrelin remains 
unknown, but the phosphorylation may associate with subcellular localization of ghrelin, 
especially des-acyl ghrelin.  
5. Ghrelin family members 
The preproghrelin, encoded by ghrelin mRNA transcript A, contains a 23 amino-acid 
signal peptide and a 94 amino-acid proghrelin (1–94). The latter includes the 28 amino 
acid mature ghrelin (1–28) and a 66 amino acid tail (29–94) (Kojima et al., 1999; Jeffery et 
al., 2005). This proghrelin can be cleaved by prohormone convertase 1/3 (PC1/3) in 
mouse gastric mucosa to generate bona fide ghrelin in vivo (Zhu et al., 2006). Different 
products of ghrelin gene have been generated by alternative splicing and post-
translational modification. 
5.1 N-octanoyl ghrelin 
Ghrelin was purified from the rat stomach through a series of steps of chromatography: gel 
filtration, two ion-exchange HPLC steps, and a final reverse-phase HPLC (RP-HPLC) 
procedure. The second ion-exchange HPLC yielded two active peaks, from which ghrelin 
and des-Gln14-ghrelin were purified, respectively (Hosoda et al., 2000b). Analysis of ghrelin 
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revealed the unique structure of a 28-amino acid peptide with its third amino acid Serine n-
octanoylated. This modification is essential for ghrelin’s activity for binding with GHSR1a. It 
is the first known case of a peptide hormone modified by a fatty acid. The sequence of 
ghrelin is highly conserved between species. Only two amino acid residues are different 
between rat and human (Kojima et al., 1999). There is no structural homology between 
ghrelin and peptide GHSs such as GHRP-6 or hexarelin. 
5.2 Des-Gln
14
-ghrelin 
A second type of ghrelin peptide has been purified from rat stomach and identified as 
des-Gln14-ghrelin (Hosoda et al., 2000b). Except for the deficiency of Gln14, des-Gln14-
ghrelin is identical to ghrelin, with the same n-octanoic acid modification and potency of 
activities. The deletion of Gln14 attributes to the CAG codon encoding Gln, which is a 
splicing signal. Analysis of ghrelin gene structure reveals that an intron exists between 
Gln13 and Gln14 of the ghrelin sequence. The 3’-end of the intron has two tandem CAG 
sequences. The AGs of these sequences may serve as the splicing signals (McKeown, 
1992). When the first AG is used as the splicing signal, prepro-ghrelin mRNA is produced 
and the second CAG is translated into Gln14. On the other hand, when the second AG is 
used, prepro-des-Gln14-ghrelin mRNA is generated to produce des-Gln14-ghrelin missing 
Gln14 (Hosoda et al., 2000b). These findings confirm that des-Gln14-ghrelin is processed 
from the ghrelin gene by alternative splicing rather than a distinct genomic product from 
ghrelin. Des-Gln14-ghrelin is present in low amounts in the stomach, indicating that 
ghrelin is the major functional form. 
5.3 Des-acyl ghrelin 
Des-acyl ghrelin, the nonacylated form of ghrelin, also exists at significant levels in both 
stomach and blood (Hosoda et al., 2000a). In blood, des-acyl ghrelin circulates in amount 
far greater than acylated ghrelin. The clearance rates of inactive forms of peptide 
hormones are often reduced compared with their respective active forms. Ghrelin in the 
plasma binds to high-density lipoproteins (HDLs) that contain a plasma esterase, 
paraoxonase, and clusterin (Beaumont et al., 2003). Because a fatty acid is attached to the 
third amino acid Serine of ghrelin via an ester bond, paraoxonase may be involved in de-
acylation of acyl-modified ghrelin. Thus parts of des-acyl ghrelin may originate from the 
de-acylation of acyl ghrelin. 
Des-acyl ghrelin does not compete the binding sites of GHS-R1a with acyl ghrelin in 
hypothalamus and pituitary. Consistent with this finding, des-acyl ghrelin shows no GH-
releasing and other endocrine activities associated with activation of GHS-R1a. However, 
des-acyl ghrelin shares with active acyl-ghrelin some non-endocrine actions, including the 
modulation of cell proliferation and adipogenesis (Cassoni et al., 2004). Emerging evidences 
suggest the existence of a distinct receptor other than GHS-R1a, which des-acyl ghrelin may 
bind with. Des-acyl ghrelin has been reported to either stimulate (Toshinai et al., 2006) or 
inhibit (Asakawa et al., 2005; Matsuda et al., 2006) food intake in a GHS-R1a independent 
pathway. It has been showed that ghrelin and des-acyl ghrelin both recognize common 
high-affinity binding sites on H9c2 cardiomyocytes (Baldanzi et al., 2002), which do not 
express the classical ghrelin receptor GHS-R1a, suggesting the existence of a novel ghrelin 
receptor subtype in the cardiovascular system. 
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5.4 Obestatin 
Recent evidence suggests that the 66 amino acid tail of proghrelin (29–94) can either 
circulate as a full-length peptide (C-ghrelin) or be processed to smaller peptides, mainly 
obestatin (11-23). Obestatin was proposed as a novel peptide derived from C terminal of 
proghrelin (Zhang et al., 2005). This new peptide was named ‘obestatin’ based on its 
appetite-suppressing potential. The structure of obestatin was deduced as a 23 amino acid 
sequence of proghrelin 53–75 according to mass spectrometric analysis. Because of the C-
terminal Gly–Lys motif, amidation of obestatin was assumed and confirmed as a 
prerequisite for its biological activity (Zhang et al., 2005). Detail mechanism on how this 
peptide is processed to a 23 amino acid peptide remains to be explored. Obestatin was 
originally extracted from rat stomach and has subsequently been shown to be an active 
circulating peptide (Zizzari et al., 2007; Harada et al., 2008). However, it had been found that 
no evidence for obestatin peptide circulating as distinct entity in the human and rat blood 
(Bang et al., 2007). Specific immunoassays directed to the N-terminus, C-terminus, and mid-
region of proghrelin (29–94) all detect the same molecule of Mr ~7kDa, suggesting that the 
only form present in circulation is close to the full length 66- amino acid C-ghrelin (Bang et 
al., 2007). Further studies are necessary to clarify this issue. 
5.5 Other ghrelin forms 
Several other minor forms of the ghrelin peptides were isolated in the purification of human 
ghrelin from the stomach (Hosoda et al., 2003). These peptides could be classified into four 
groups by the type of acylation at the third amino acid Serine: nonacylated, octanoylated 
(C8:0), decanoylated (C10:0), and decenoylated (C10:1). Two kinds of different length 
peptides, either 27 or 28 amino acids, were found. The 27 amino acid peptide lacks the C 
terminal Arg28 and derives from the same ghrelin precursor. Both synthetic octanoylated 
and decanoylated ghrelins increase the concentration of intracellular Ca2+ in GHS-R-
expressing cells and stimulate GH release in rats to a similar degree. 
The expression of a novel human mRNA transcript designated as exon 3-deleted mRNA 
transcript has been reported in breast and prostate cancer (Yeh et al., 2005). A murine 
homologue, exon 4-deleted mRNA transcript, has also been identified in a widely range of 
tissues (Jeffery et al., 2005). Deletion of exon 3 from the preproghrelin transcript results in a 
truncated C-peptide with a unique 16-amino-acid peptide tail, COOH-terminal D3 peptide, 
which begins with a potential peptide cleavage site [Arg–Arg]. Previous studies indicate 
that this unique COOH-terminal D3 peptide (RPQPTSDRPQALLTSL) does not affect cell 
proliferation or cell apoptosis in prostate cancer cell lines. However, the comprehensive 
expression of this C-ghrelin suggests that it may possess some unidentified functions. 
6. Tissue distribution of ghrelin 
6.1 Stomach and other gastrointestinal organs 
In all vertebrate species, stomach is the primary organ producing ghrelin (Ariyasu et al., 
2001). Ghrelin immune-reactive cells are more abundant in the fundus than in the pylorus 
(Date et al., 2000; Tomasetto et al., 2001; Yabuki et al., 2004). In situ hybridization and 
immunohistochemical analysis indicate that ghrelin-containing cells are a distinct endocrine 
cell type found in the gastric mucosa (Date et al., 2000; Rindi et al., 2002). Four types of 
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endocrine cells have been identified in the oxyntic mucosa: ECL cells, D cells, 
enterochromaffin (EC) cells, and X/A-like cells (Capella et al., 1969; Solcia et al., 1975; Grube 
& Forssmann, 1979). The granule contents of X/A-like cells had not been identified until the 
discovery of ghrelin. The X/A-like cells contain round, compact, electron dense granules 
that are filled with ghrelin (Date et al., 2000; Dornonville de la Cour et al., 2001; Yabuki et 
al., 2004). The X/A-like cells account for about 20% of the endocrine cell population in adult 
oxyntic glands and can be stained by an antibody specific to the NH2-terminal, acylated 
portion of ghrelin, indicating that ghrelin in the secretory granules of X/A-like cells has 
already been acylated. However, the number of X/A-like cells and ghrelin concentration in 
the fetal stomach is very low and gradually increases after birth (Hayashida et al., 2002).  
Ghrelin-immunoreactive cells are also found in the duodenum, jejunum, ileum, and colon 
(Date et al., 2000; Hosoda et al., 2000a; Sakata et al., 2002), among which ghrelin 
concentration gradually decreases from the duodenum to the colon. The pancreas is another 
ghrelin-producing organ especially during the embryo development and the production of 
ghrelin decreases rapidly after birth. The cell type that produces ghrelin in the pancreatic 
islets remains controversial, whether it might be the ǂ cells, ǃ cells, newly identified islet 
epsilon (ǆ) cells, or an unknown novel type of islet cells (Date et al., 2002; Wierup et al., 2002; 
Prado et al., 2004; Wierup et al., 2004). 
6.2 Central nervous system — Hypothalamus 
Ghrelin is the endogenous ligand for GHS-R which is mainly expressed in the 
hypothalamus and pituitary (Howard et al., 1996; Guan et al., 1997). Despite that the 
content of ghrelin is very low (Kojima et al., 1999; Hosoda et al., 2000a), ghrelin immnuo-
reactivity has been detected in the hypothalamic arcuate nucleus, an important region for 
controlling appetite (Kojima et al., 1999; Lu et al., 2002). In addition, ghrelin immune-
reactive cell bodies in the hypothalamus are distributed in a continuum filling the inter-
nuclear space between the lateral hypothalamus (LH), arcuate (ARC), ventromedial 
(VMH), dorsomedial (DMH), and paraventricular hypothalamic nuclei (PVH) and the 
ependymal layer of the third ventricle (Cowley et al., 2003). These ghrelin-containing 
axons innervate neurons that contain neuropeptide Y (NPY) and agouti-related protein 
(AgRP) and may stimulate the release of these orexigenic peptides. These histological 
findings are consistent with the functional studies in which injection of ghrelin into the 
cerebral ventricles of rats potently stimulates food intake.  
Ghrelin has also been found in the pituitary gland (Korbonits et al., 2001a; Korbonits et 
al., 2001b), where it may influence the release of GH in an autocrine or paracrine manner. 
Stimulation of primary pituitary cells with ghrelin increases their intracellular Ca2+ 
concentration (Bennett et al., 1997; Guan et al., 1997; McKee et al., 1997a). The expression 
level of ghrelin in the pituitary is high in the neonates and declines with puberty. 
Pituitary tumors, such as adenomas, corticotroph tumors, and gonadotroph tumors 
contain ghrelin peptides as well. 
6.3 Other tissues 
Two major forms of ghrelin: n-octanoyl and des-acyl ghrelin, are found in circulation 
(Hosoda et al., 2000a). The concentrations of n-octanoyl ghrelin and total ghrelin in human 
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plasma are 10–20 fmol/ml and 100–150 fmol/ml respectively. Plasma ghrelin concentration 
increases in fasting condition and reduces after habitual feeding (Cummings et al., 2001; 
Tschop et al., 2001a). In addition, plasma ghrelin level is lower in obese subjects than the age 
matched lean controls (Tschop et al., 2001b; Hansen et al., 2002; Shiiya et al., 2002).  
Ghrelin mRNA is also detected in the kidney, especially in the glomeruli (Mori et al., 2000; 
Gnanapavan et al., 2002). Moreover, peptide extracts from mouse kidney contain both n-
octanoyl and des-acyl ghrelin. Significant relationship between plasma ghrelin 
concentration and the serum creatinine level has been demonstrated. In patients with end-
stage renal disease, plasma ghrelin level increases 2.8-fold compared with those with normal 
renal function (Yoshimoto et al., 2002). This finding suggests that the kidney is an important 
organ for clearance and/or degradation of ghrelin. 
In the reproductive system, ghrelin immune-reactive cells have been identified in interstitial 
Leydig cells and at a low level in Sertoli cells (Barreiro et al., 2002; Tena-Sempere et al., 
2002). The ghrelin receptor has also been detected in germ cells, mainly in pachytene 
spermatocytes, as well as in somatic Sertoli and Leydig cells (Gaytan et al., 2004). During 
embryo development, ghrelin-immunoreactive cells are detectable in cytotrophoblast cells 
in first-trimester human placenta but disappear in third-trimester placenta (Gualillo et al., 
2001). Ghrelin-containing cells are also detected in syncytiotrophoblast cells of the human 
placenta and in the cytoplasm of labyrinth trophoblasts of the rat placenta. 
6.4 Ghrelin producing cell lines 
Ghrelin can be detected in several cultured cell lines. One of which is TT cells, a human 
thyroid medullary carcinoma cell line (Kanamoto et al., 2001). TT cells express ghrelin 
mRNA. Conditioned medium and cellular extracts of TT cells contain both n-octanoyl 
ghrelin and des-acyl ghrelin. Other cultured cells such as the kidney-derived cell line NRK-
49F (Mori et al., 2000), gastric carcinoid ECC10 cells (Kishimoto et al., 2003), and the 
cardiomyocyte cell line HL-1 (Iglesias et al., 2004) express ghrelin as well. 
Some patients with neuroendocrine tumors also accompany with high level of ghrelin in 
plasma. It had been reported that a patient with a malignant neuroendocrine pancreatic 
tumor with ghrelin immunoreactivity and a high circulating ghrelin level (Corbetta et al., 
2003). A patient with a metastasizing gastric neuroendocrine tumor has also been reported 
to have extremely high circulating level of ghrelin (Tsolakis et al., 2004). In the latter case, 
the patient developed diabetes mellitus and hypothyroidism. In both cases, GH and IGF-I 
levels were within the normal range, and the patients had no clinical features of acromegaly. 
7. Regulation of ghrelin biosynthesis 
In the 5’-flanking region of the ghrelin gene, several E-box consensus sequences exist 
(Kanamoto et al., 2004). Destruction or site-directed mutagenesis of these sites decreases the 
promoter activity in TT cells. Upstream stimulatory factors (USF), members of the bHLH-LZ 
family of transcription factors, bind to these E-box elements and may thus modulate the 
expression of ghrelin gene. Ghrelin promoter activity in ECC10 cells is up-regulated by 
glucagon and its second messenger cAMP (Kishimoto et al., 2003), suggesting that a high 
level of ghrelin production may be related to increased glucagon in fasting condition. 
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The biosynthesis of ghrelin is tightly linked with the energy status and regulated by 
different nutritional ingredients. Fasting increases ghrelin, des-acyl ghrelin and C-ghrelin, 
while demonstrates no effect on obestatin (Zhang et al., 2005; Bang et al., 2007). Conversely, 
feeding decreases ghrelin, des-acyl ghrelin and C-ghrelin (Zhang et al., 2005; Bang et al., 
2007). Postprandial acylated ghrelin level falls more quickly than total ghrelin. The 
postprandial decrease of ghrelin can be attributed mainly to the increase of the serum 
glucose concentration, because the total ghrelin, acyl ghrelin, and des-acyl ghrelin all 
decrease significantly after a high-carbohydrate meal (Sedlackova et al., 2008). Other 
nutrients, such as high-fat meal, induces minor (Monteleone et al., 2003) but more persistent 
(Erdmann et al., 2003; Foster-Schubert et al., 2008) post-prandial suppression in circulating 
total ghrelin than high-carbohydrate meal in humans. Ingestion of either medium-chain 
fatty acids (MCFAs, such as n-octanoic acid) or medium-chain triglycerides (MCTs, such as 
glyceryl trioctanoate) increases the stomach contents of acyl ghrelin without changing the 
total ghrelin in mouse (Nishi et al., 2005). This finding suggests that medium-chain fatty 
acids can be utilized directly for the acyl modification of ghrelin. Oral ingestion of a 
physiological dose of essential amino acids leads to a continuous rise in serum ghrelin level 
in humans (Groschl et al., 2003; Knerr et al., 2003). Insoluble dietary fiber ingestion may 
influence ghrelin level as well (Gruendel et al., 2007). 
Chronic energy imbalance such as obesity or anorexia also alters ghrelin production. Body 
mass index in human is negatively correlated with the production of ghrelin. Plasma ghrelin 
concentration is low and post-prandial decrease in ghrelin is attenuated in the obese 
individuals (Erdmann et al., 2005). Patients with anorexia nervosa have significant increase 
in serum total and acyl ghrelin levels (Harada et al., 2008), which return to normal when the 
disease is cured and the body weight restored (Otto et al., 2001). Furthermore, total ghrelin 
level is inversely associated with fat cell volume (Purnell et al., 2003) and specifically in 
women with total fat mass and fat mass/lean mass ratio, whereas in men with abdominal 
fat mass and fat distribution index (Makovey et al., 2007). 
There may also be a developmental regulation of ghrelin gene-derived peptides 
expression. It has been showed that plasma total ghrelin concentration decreases abruptly 
after birth, contrasting with a 3-fold increase in the concentration of acylated ghrelin 
(Chanoine & Wong, 2004).  
Little has been known on the intracellular mechanism by which ghrelin expression is 
regulated. Our studies suggest that gastric mammalian target of rapamycin (mTOR) activity 
is critical for the modulation of ghrelin production (Xu et al., 2009; Xu et al., 2010).  
8. Ghrelin receptors and their distribution 
The GHS receptor gene is located on chromosome 3q26.2 and encodes for two transcripts, 1a 
and 1b which encode a full-length receptor GHS-R1a and a shortened version GHS-R1b 
respectively (McKee et al., 1997a). Type 1a encodes a 366-amino acid polypeptide containing 
all seven TM (transmembrane) domains, while type 1b encodes a truncated 289-amino acid 
polypeptide with only five TM domains. Both sequences are identical from the Met 
translation site to Leu at the 265th amino acid position (Howard et al., 1996). 
The GHS-R1a is comprehensively distributed in a variety of tissues and has high affinity 
with ghrelin and GHSs. GHS-R1b also has a widespread expression but does not compete 
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with GHS-R1a to bind ghrelin or synthetic GHS (Gnanapavan et al., 2002) and its function 
remains controversial. GHS-R1a is highly expressed in the hypothalamus and pituitary, 
consistent with ghrelin’s functional role in the control of appetite and growth hormone 
release. 
8.1 Type 1a GHS receptor 
The GHS-R1a gene contains a single, ~2kb intron separating two exons and encodes a GPCR 
with seven transmembrane (TM) domains (McKee et al., 1997b). Its ligand activation domains 
are in the second TM domain (TM2) and the third TM domain (TM3). These key amino acid 
residues are essential for binding and activation by different ligands, and have been 
evolutionarily conserved for 400 million years, highlighting its importance in fundamental 
physiological processes (Palyha et al., 2000). GHS-R1a mRNA is detected at 18 and 31 weeks of 
gestation, indicating that ghrelin might be active early in fetal development (Hayashida et al., 
2002; Nakahara et al., 2006). Comparison of the predicted human rat, pig and sheep GHS-R1a 
amino acid sequences reveals 91.8–95.6% sequence homology (Palyha et al., 2000). 
8.1.1 GHS-R1a structure 
The human GHS-R1a consists of 366 amino acids with a molecular mass of approximately 41 
kDa (Howard et al., 1996; Schwartz et al., 2006) and belongs to family A of G-protein-
coupled receptors (GPCRs) (Bockaert & Pin, 1999). It spans the membrane with seven ǂ-
helix hydrophobic domains which joint each other by three intra- and extracellular domains, 
beginning with an extracellular N-terminal domain and ending with an intracellular C-
terminal domain (Bockaert & Pin, 1999). The N-terminal domain forms a ǃ-hairpin structure 
and the TM domains a round calyx-like structure which is attributed to Pro residues in the 
center of the TM helices. TM3 occupies the central position among the TM segments and 
TM5 is the most peripheral (Pedretti et al., 2006).  
GHS-R1a possesses three conserved residues Glu-Arg-Tyr at the intracellular end of 
transmembrane 3 (TM3) domain in position 140–142 (ERY/DRY motif), which are important 
for the isomerization between the active and inactive conformation, and two cysteine 
(Cys116 and Cys198) residues on the extracellular loop 1 and 2 respectively forming a 
disulfide bond (Bockaert & Pin, 1999; Petersenn, 2002). Mutagenesis of TM sites reveals 
much of the functional domains within the GHS-R1a. Amino acids like E124, D99, and R102 
of TM2 and TM3 contribute to the ligand activation, while E124, F119, and Q120 of TM3 
mediate binding activity (Palyha et al., 2000). Consistent with this finding, investigation 
using antibody-binding studies directed at different regions of the ghrelin receptor, has also 
identified the amino acid residue E124 as an important binding site for GHSs, mediating a 
salt bridge interaction with basic moieties that appear to act independent of receptor 
activation (Feighner et al., 1998). Meanwhile, the importance of the hydrophobic octanoyl 
moiety attached to ghrelin’s serine-3 residue to GHS-R1a binding has been demonstrated 
(Bednarek et al., 2000), and an ‘active core’ sequence of Gly-Ser-Ser (octanoyl)-Phe essential 
for receptor activation has been identified. 
8.1.2 Ligand binding domains 
GHS-R1a transduces information provided by both ghrelin and GHSs. This concept has 
been explained based on the existence of a common binding domain as demonstrated by 
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molecular modeling and site-directed mutagenesis studies (Feighner et al., 1998). The 
binding domain should allow a conserved structure of agonists to recognize a 
complementary binding pocket that accommodates the variable part of the ligand 
overlapping in the agonist binding site (Bondensgaard et al., 2004). This domain is imposed 
by the orientation of transmembrane segments that determine the stereo- and geometric 
specificity of the ligand’s entry and binding to the transmembrane core. 
The binding domain of GHS-R1a involves six amino acids located in TM3, TM6 or TM7 
(Holst et al., 2006). In addition, binding of the natural ligand ghrelin with GHS-R1a requires 
the ligand to interact with one pocket formed by polar amino acids in TM2/TM3 and one 
formed by non-polar amino acids in TM5/TM6, respectively (Pedretti et al., 2006). The 
synthetic peptidyl and non-peptidyl GHSs share a common binding pocket in the TM3 
region of the GHS-R1a, although there are other distinct binding sites in the receptor that 
seem to be selective for particular classes of agonists (Feighner et al., 1998). While the main 
binding pocket for small amines is deep in the pocket created by the TM domains, small 
peptides bind to extracellular epitopes as well. The basic amine common to peptidyl 
(GHRP-6) and non-peptidyl (MK-0677) GHS establishes an electrostatic interaction with 
Glu124 in the TM3 domain (Feighner et al., 1998). Substitution of glutamine for glutamic acid 
[Glu124Gln mutant] in human GHS-R1a inactivates its function. Furthermore, mutation of 
Arg283 in TM6, which interacts with Glu124, abolishes both agonist-induced activation and 
constitutive signaling (Feighner et al., 1998; Holst et al., 2003). In addition, disruption of the 
disulfide bond between Cys116 and Cys198 in the extracellular portion of the receptor by 
mutating Cys116 into alanine [Cys116Ala mutant] completely abolishes the activity of all 
agonists (Feighner et al., 1998; Palyha et al., 2000). 
8.1.3 Constitutive activity 
Evidences on the physiological relevance of GHS-R1a constitutive activity are steadily 
emerging. The molecular mechanism of such constitutive activity relates to three aromatic 
residues located in TM6 and TM7, namely PheVI:16, PheVII:06 and PheVII:09. These 
residues promote the formation of a hydrophobic core between helices 6 and 7 to ensure 
proper docking of the extracellular end of TM7 into TM6 (Holst et al., 2004). Phe279Leu and 
Ala204Glu polymorphisms have been reported to be associated with short stature and 
obesity respectively (Wang et al., 2004), indicating that constitutive activity of GHS-R1a in 
vivo might be imperative for normal growth and development of the human body (Holst & 
Schwartz, 2006). The Phe279 mutation is a conservative amino acid exchange in the sixth 
transmembrane domain of GHS-R1a, and the Ala204 is located in the second extracellular 
loop. Both amino acid residues are highly conserved (Wang et al., 2004). 
When transfected to HEK-293 cells, the derived GHS-R1a receptor displays reduced basal 
activity and lower expression at the plasma membrane (Pantel et al., 2006), although 
responsiveness to ghrelin is intact (Holst & Schwartz, 2006; Pantel et al., 2006). In addition, 
GHS-R1a transfection leads to constitutively stimulated CRE (cAMP-responsive element) 
activity in HEK-293 cells (Holst et al., 2003). When overexpressed in COS-7 cells, GHS-R1a 
possesses a constitutive activity in the turnover of IP3, which is approximately 50% of the 
maximal agonist induced activity (Holst et al., 2003; Holst et al., 2006). However, GHS-R1a 
does not show any constitutive activity in the pituitary cell line RC-4B/ C40, indicating that 
GHS-R1a constitutive activity may depend on the cellular context (Falls et al., 2006). The 
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only known ligand blocking GHS-R1a constitutive activity is D-Arg1-D-Phe5-D-Trp7,9-Leu 11-
substance P (Holst et al., 2003; Holst et al., 2006). 
8.1.4 Endocytosis of GHS-R1a 
Kinetic studies of GHS-R1a internalization based on radioligand binding experiments and 
confocal microscopy have demonstrated that GHSR-1a is internalized in a time dependent 
manner, which peaks at approximately 20 min after ghrelin stimulation. The ghrelin- GHSR-
1a complex is internalized principally by a clathrin-mediated mechanism and through the 
endosomal trafficking pathway (Camina et al., 2004). Once the ligand-receptor complex is 
internalized into vesicles, GHSR-1a is sorted into endosomes to be recycled back to 
membrane. About 360 min after agonist removal, the level of GHS-R1a receptors on the cell 
surface rises close to 100% of its original level. The process is not affected by cycloheximide, 
suggesting that GHS-R1a originates from endosomes rather than de novo receptor synthesis. 
This notion is further demonstrated by the observation that fluorescence associated with 
GHS-R1a-EGFP in CHO cells reappears on the membrane in the similar kinetics after a 
ghrelin pulse. Moreover, fluorescence emitted by the EGFP-labeled GHS-R1a in cells co-
localizes with the early endosomal protein 1 but not with cathepsin (lysosomal marker), 
indicating that GHS-R1a is not targeted to lysosomal compartments. Thus, most of GHS-R1a 
appearing at the cell surface originates from endocytosed receptors, leading to the complete 
restoration of binding capacity and functionality.  
Function experiments also demonstrate the theory of GHS-R1a recycling. GH response to 
twice consecutive pulses of ghrelin is blunted when pulses are separated by short interval 
(60 min), but it restores the initial amplitude when the second pulse is administered after 
180, 240 or 360 min, which fits well with the kinetics of receptor recycling. The slower 
recycling (3–6 h) of this receptor compared to other GPCRs is determined by the stability 
of the complex GHSR-1a/ǃ-arrestin during clathrin-mediated endocytosis because this 
complex appears to dictate the profile of the receptor re-sensitization (Luttrell & 
Lefkowitz, 2002).  
In the normal healthy organism, ghrelin receptor desensitization and endocytosis govern the 
ability of cells to respond to ghrelin and thereby regulate intracellular signaling to avoid a 
permanent stimulation of target cells. Moreover, receptor re-sensitization determines the 
frequency of the response to ghrelin. Deficiencies in this attenuation system may lead to an 
uncontrolled or defective stimulation of target cells, which causes alteration in its 
intracellular signaling and subsequent pathological changes. 
8.2 Non-type 1a GHS receptors 
Remarkable differences in the binding profile among ghrelin, synthetic peptidyl 
(hexarelin) and non-peptidyl (MK-0677) GHSs have been reported (Ong et al., 1998a; Ong 
et al., 1998b; Papotti et al., 2000; Holst et al., 2004) , suggesting the presence of a novel 
unidentified receptor subtype in tissues that do not express GHS-R1a or express the 
receptor at a low level. The existence of various GHS-R1a homologues, the lack of a 
definite phenotype in GHS-R1a knockout mice as well as the presence of multiple 
endogenous ghrelin-like ligands, indicate the existence of multiple receptors for ghrelin 
and GHSs. 
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8.2.1 Other GPCR homologues of GHS-R1a 
Based on its peptide sequence and intracellular signaling, GHS-R1a is often included in a 
small family of receptors for small polypeptides such as the receptor for motilin (52% 
homology), neurotensin receptor-1 (NTS-R1) and NTS-R2 subtype (33–35% homology), 
neuromedin U receptor-1 (NMU-R1) and NMU-R2 subtype ( ~ 30% homology), and the 
orphan receptor GPR39 (27–32% homology) (McKee et al., 1997b; Tan et al., 1998). 
GHS-R1a shares the highest homology with GPR38, the receptor for motilin (McKee et al., 
1997b; Petersenn, 2002). GRP38 is mostly distributed in the thyroid gland, bone marrow, 
stomach and gastrointestinal smooth muscles, and less widely expressed in the 
neuroendocrine tissues than GHS-R1a. Both GRP38 and GHS-R1a receptors mediate the 
pulsatile biological effects upon continuous stimulation and increase gastrointestinal 
motility. In response to motilin, GRP38 couples with Gǂq/Gǂ13, increases cytosolic free 
Ca2+ by an IP3-dependent Ca2+ release mechanism (Huang et al., 2005).  
Another group of GPCR homologues of GHS-R1a are NTS receptor, namely NTS-R1 and 
NTS-R2. NTS is a 13-amino-acid polypeptide, which has high sequence homology with 
neuromedin N. In the CNS, NTS-Rs have been identified in the hypothalamus, amygdala 
and nucleus accumbens. NTS-Rs involve in modulation of the dopaminergic system in the 
CNS, while act on the small intestine endocrine cells to increases acid secretion and regulate 
smooth muscle contraction in the peripheral tissues (Vincent et al., 1999). NTS-R1 mainly 
functions through Gq/11-PLC/IP3, but it also activates cGMP/cAMP signaling and ERK1/2 
phosphorylation (Amar et al., 1985; Bozou et al., 1989; Poinot-Chazel et al., 1996; Vincent et 
al., 1999). NTS-R2 induces intracellular Ca2+ signaling and ERK phosphorylation (Botto et 
al., 1997; Sarret et al., 2002).  
Neuromedin U is a 23～25 amino acids polypeptide which is the ligand for other members 
of this receptor family, the NMU-R1/R2 receptors. NMU is highly conserved among species 
and widely distributed in the body especially at high levels in the brain where it mediates 
effects on food intake opposite to ghrelin (Jethwa et al., 2006), likely by cross-talking with 
the anorectic leptin system (Jethwa et al., 2006; Nogueiras et al., 2006). The NMU-R1 subtype 
is mainly expressed in the periphery, while NMU-R2 is mostly in the brain (Brighton et al., 
2004). Both receptors are involved in the regulation of smooth muscle contraction, gastric 
acid secretion, insulin secretion, ion transport in the gut, feeding behavior and stress 
(Brighton et al., 2004). Both NMU-R1 and NMU-R2 signal through Gq/11, PLC and Ca2+ 
(Brighton et al., 2004).  
The other GHS-R1a homologue is GRP39, which remains controversial about whether or 
not obestatin binds it (Zhang et al., 2005; Dun et al., 2006; Lauwers et al., 2006; Tremblay 
et al., 2007). GRP39 is distributed in a variety of tissues, but mostly in brain regions 
(McKee et al., 1997b). Compared with GHS-R1a and GRP38, GRP39 has a very long C-
terminal and two potential palmitoylation sites, which creates a 4th intracellular loop 
(Morello & Bouvier, 1996; McKee et al., 1997b). Activation of GRP39 by Zn2+ induces PLC 
signaling, CRE- and SRE-dependent transcriptional activity, and cAMP production (Holst 
et al., 2007). Except for the sequence homology with GHS-R1a, the relationship between 
GPR39 and ghrelin system remains indefinable. 
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8.2.2 Type 1b GHS receptor 
Type 1b GHS receptor (GHS-R1b) contains 298 amino acids corresponding to the first five 
TM domains encoded by exon 1, plus a unique 24 amino acid tail encoded by an 
alternatively spliced intron sequence. Neither ghrelin nor GHS binds or causes any response 
to GHS-R1b receptor (Smith et al., 1997) in cells transfected with GHS-R1b. Since GHS-R1b is 
comprehensively expressed in various tissues (Gnanapavan et al., 2002), it is reasonable to 
assume that this receptor possesses some unidentified biological functions. A report in 2007 
has revealed that GHS-R1b decreases the cell surface expression of GHS-R1a and acts as a 
repressor of the constitutive activity of GHS-R1a when overexpressed in HEK-293 cells (Chu 
et al., 2007). This finding suggests that GHS-R1b may act as an endogenous modulator for 
GHS-R1a constitutive activity. This fascinating action may attribute to its capability of 
forming heterodimers with full length GPCR receptors, causing altered biological properties 
compared to the original receptor. 
8.2.3 CD36 receptor  
CD36, a membrane glycoprotein of Mr ～84kDa belonging to the scavenger receptor type-B 
family (Bodart et al., 1999), distributes in a wide range of tissues including adipose tissue, 
platelets, monocytes/macrophages, dendritic cells, and microvascular endothelium 
(Febbraio et al., 2001). CD36 is implicated in multiple physiological functions such as fatty 
acid/lipid transportation, insulin resistance, antigen presentation and regulation of 
angiogenesis, as well as pathophysiological processes related to the formation of 
macrophage foam cell and atherosclerotic lesions (Febbraio et al., 2001). In a perfused heart 
preparation, hexarelin elicits vasoconstriction. This effect is likely mediated via CD36 
because no similar effect occurs in CD36 null mice and rats (Bodart et al., 2002). The signal 
transduction pathways mediating the vasoconstrictive effect of hexarelin involve both L-
type calcium channels and protein kinase C (Bodart et al., 1999). 
The effect of hexarelin on the inhibition of cholesterol accumulation might be also mediated 
by CD36. Hexarelin reduces internalization of oxLDL by interfering with CD36 on the same 
interaction site as that of oxLDL (Avallone et al., 2006). In addition, hexarelin increases 
cholesterol efflux in macrophages through activation of CD36 and GHS-R1a which enhances 
expression of the ABCA1 and ABCG1 transporters and therefore improves cholesterol efflux 
from macrophages (Avallone et al., 2006).  
8.3 Tissue distribution of ghrelin receptors 
The ghrelin receptor is ubiquitously distributed in both the CNS and peripheral tissues. In 
the rat brain, GHS-R1a signals are detected in hypothalamic nuclei including anteroventral 
preoptic nucleus, anterior hypothalamic area, suprachiasmatic nucleus, lateroanterior 
hypothalamic nucleus, supraoptic nucleus, ventromedial hypothalamic nucleus, arcuate 
nucleus, paraventricular nucleus and tuberomammillary nucleus as well as in the pituitary 
gland (Guan et al., 1997). This distribution is consistent with its physiological function 
associated with energy metabolism and GH release. In addition to the hypothalamus, GHS-
R1a mRNA is also expressed in several other discrete regions of the rat brain such as dentate 
gyrus, CA2 and CA3 regions of the hippocampal formation, thalamic regions, and several 
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nuclei within the brain stem including pars compacta of the substantia nigra, ventral 
tegmental area, median and dorsal raphe nuclei and laterodorsal tegmental nucleus (Guan 
et al., 1997). GHS-R1a may therefore play a role in the control of other functions such as 
memory, anxiety and some endocrine physiology.  
In the peripheral tissues, GHS-R1a mRNA is detected in the stomach and intestine (Date et 
al., 2000), pancreas (Guan et al., 1997), kidney (Mori et al., 2000), heart and aorta (Nagaya et 
al., 2001c), adipose tissues (Gnanapavan et al., 2002), as well as in various endocrine 
neoplasms (de Keyzer et al., 1997; Korbonits et al., 2001a; Papotti et al., 2001). Such a wide 
distribution of GHS-R1a is consistent with the reported broad functions beyond the control 
of GH release and food intake. Existence of a novel ghrelin receptor subtype with a binding 
profile different from the GHS-R1a in the peripheral tissues, in human thyroid and breast 
tumors, as well as in related cancer cell lines has been reported but requires further 
confirmation (Cassoni et al., 2001; Volante et al., 2002). 
9. Intracellular signaling pathways of ghrelin receptors 
Binding of ghrelin to GHS-R1a induces a profound change in the transmembrane ǂ helices, 
which alters the conformation of intracellular loops and uncovers masked G protein binding 
sites interacting with G proteins. This interaction promotes the release of guanosine 
diphosphate (GDP) bound to the G protein ǂ subunit and exchange for guanosine 
triphosphate (GTP), followed by activation of G protein subunits which initiates 
intracellular signaling responses via a series of intracellular molecules. 
Intracellular calcium is the well-characterized signaling mode used by GHS-1a receptor 
related studies, as its endogenous ligand ghrelin was discovered by monitoring intracellular 
calcium flux in recombinant cells expressing the GHSR-1a (Howard et al., 1996; Kojima et 
al., 1999). Ghrelin activates at least two signal transduction pathways associated with 
calcium regulation. In neuropeptide Y (NPY)-containing neurons of the hypothalamus, 
ghrelin induced increase in intracellular calcium concentration is dependent on the calcium 
influx through N-type calcium channels activated by the AC-cAMP-PKA signaling pathway 
following the binding of the Gs protein to GHS-R1a (Kohno et al., 2003). In addition to this 
cAMP/ PKA pathway, ghrelin also evokes the intracellular calcium signaling by an 
alternative pathway through Gq/PLC/IP3 (Howard et al., 1996). Coupling of ghrelin to the 
GHS-R1a activates phospholipase C to generate IP3 and diacylglycerol (DAG). IP3 then 
triggers the release of calcium from IP3 sensitive intracellular calcium stores (Deghenghi et 
al., 2001), whereas DAG is responsible for the activation of PKC. The initial calcium current 
is followed by sustained calcium entry through L- and T-type calcium channels via 
membrane depolarization (Chen et al., 1990; Smith et al., 1993). Different binding sites on the 
GHSR-1a have been proposed to potentially account for these two distinct components of 
ghrelin receptor signaling (Cassoni et al., 2001). 
In addition to the well-characterized activation of calcium currents, ghrelin also activates the 
MAP kinase (MAPK) signaling pathway. In 3T3-L1 preadipocytes, ghrelin induces a rapid 
activation of ERK1/2, while inhibition of ERK signaling by PD98059 significantly attenuates 
the proliferative activities of ghrelin (Kim et al., 2004). In human and rat adrenal zona 
glomerulosa cells, the proliferative effect of ghrelin involves the activation of tyrosine 
kinase-dependent MAPK p42/p43 mechanism and appears to be independent of PKA and 
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PKC (Carreira et al., 2004; Mazzocchi et al., 2004). Pretreatment of cells with Gi/o inhibitor 
(pertussis toxin), PKC inhibitors (staurosporin and GF109203X), or PI3K inhibitor 
(wortmannin) significantly attenuates ghrelin-induced ERK1/2 phosphorylation, suggesting 
that multiple signaling pathways are involved in activation of MAPK induced by ghrelin 
(Mousseaux et al., 2006). 
AMP-activated protein kinase (AMPK) plays a pivotal role in the regulation of energy 
metabolism. Ghrelin increases food intake through the activation of AMPK and acetyl-
CoA carboxylase (ACC), and the inhibition of fatty acid synthase (FAS) in the ventral 
medial hypothalamus (Lopez et al., 2008). The molecular mechanism by which ghrelin 
regulates AMPK is still unknown, although tumor suppressor LKB1 may be an upstream 
regulator of AMPK kinase (Hardie, 2004). It is worth noting that AMPK’s metabolic 
activity induced by ghrelin receptor is tissue-specific. In the rat liver, ghrelin inhibits 
AMPK activity to evoke a series of lipogenic and glucogenic gene expression and an 
increase in triglyceride content without changing the mitochondrial oxidative enzyme 
activities (Barazzoni et al., 2005). Ghrelin can also inhibit vascular inflammation through 
the activation of the calmodulin-dependent kinase kinase (CaMKK), AMPK and 
endothelial nitric oxide synthase (eNOS) (Xu et al., 2008). 
Insulin signaling pathway is also regulated by ghrelin through the insulin receptor substrate 
(IRS-1) associated PI3K activity and Akt phosphorylation. In hepatoma cells, ghrelin increases 
IRS-1 associated PI3K activity (Murata et al., 2002) and inhibits Akt kinase activity. In addition, 
ghrelin partially reverses the down-regulation of insulin on phosphoenol pyruvate 
carboxykinase (PEPCK) mRNA expression, a rate-limiting enzyme of gluconeogenesis.  
10. Ghrelin’s functions 
Few gastrointestinal peptide hormones attract more attention than ghrelin, not only because 
it is the only identified orexigenic hormone circulating in the blood, but also it possesses the 
unique structure of octanoyl acid modification. In addition to its classical effect on GH 
release, ghrelin exercises a wide range of physiological functions ranging from regulation of 
food intake and energy metabolism, control of glucose and lipid homeostasis, modulation of 
cardiovascular function, to immunomodulation. 
10.1 Ghrelin and energy balance 
10.1.1 Ghrelin and obesity  
Hyperphagia, weight gain, and increased adiposity occurs after chronic administration of 
ghrelin either systemically or intracerebroventricularly (Tschop et al., 2000; Nakazato et al., 
2001). Chronic central administration of ghrelin increases adipose deposition independently 
of food intake (Nakazato et al., 2001) in pair-fed animals. Further studies demonstrate that 
central ghrelin stimulates triglyceride (TG) uptake and lipogenesis, while inhibits lipid 
oxidation in white adipocytes (Theander-Carrillo et al., 2006). Peripheral daily 
administration of ghrelin for two weeks causes a significant increase in fat mass as 
measured by dual energy X-ray absorptiometry (DXA) (Tschop et al., 2000). Consistent with 
these observations, the ghrelin receptor null mice are protected against the full development 
of diet-induced obesity (Zigman et al., 2005). 
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10.1.2 Ghrelin and cachexia/anorexia 
Cachexia is characterized by involuntary weight loss due to persistently negative nitrogen 
balance resulting from a diverse series of pathological conditions such as malnutrition, 
chronic infectious diseases, immunodeficiency and malignancy. Cachexia is always 
accompanied by anorexia, while the reduction in food intake alone cannot explain the 
metabolic changes and wasting associated with cachexia. Ghrelin and ghrelin receptor 
agonists are fascinating candidates for the treatment of cachexia, due to their unique 
anabolic effects such as stimulating GH secretion, food intake, gastric motility and 
adiposity. High levels of circulating acylated ghrelin are detected in cachexia patients 
associated with lung cancer (Shimizu et al., 2003), chronic heart failure (Nagaya et al., 
2001b), renal failure (Yoshimoto et al., 2002), chronic liver disease (Tacke et al., 2003) and 
anorexia nervosa (Otto et al., 2001), which may represent a compensatory response to an 
organism’s wasting. Both ghrelin and acylated to total ghrelin ratio are elevated in cancer 
induced cachexia and inversely associated with body mass index (BMI). Whether 
increased circulating ghrelin levels indicate a ghrelin resistance in cachexia remains to be 
determined. 
10.2 Ghrelin and food intake  
Both animal experiments and clinical studies demonstrate that ghrelin induces a rapid 
increase in food intake in rodents and humans (Muccioli et al., 2002). Originating from the 
stomach, ghrelin activates arcuate NPY/AgRP neurons to increase the secretion of NPY, 
AgRP and GABA. NPY subsequently modulates the activity of postsynaptic secondary 
order neurons in the paraventricular nucleus, dorsomedial nucleus and lateral hypothalamic 
area to stimulate food intake, while GABA inactivates the proopiomelanocortin neurons and 
inhibits the anorectic melanocortin signaling pathway.  
The intracellular mechanisms that mediate NPY/AgRP neuronal activation in response to 
ghrelin in appetite regulation have been demonstrated to be associated with the lipid 
metabolism in the hypothalamus (Lopez et al., 2008). After binding of ghrelin, the ghrelin 
receptor activates hypothalamic AMPK. AMPK then phosphorylates the acetyl-CoA 
carboxylase, decreases malonyl-CoA level, and suppresses lipid synthesis (Kola et al., 
2005), leading to the activation of carnitine palmitoyltransferase 1 (CPT1). Activated CPT1 
then accelerates lipid transport into mitochondria to catabolize lipid. Ghrelin regulates 
mitochondrial oxidation in the hypothalamic cells mainly through uncoupling protein 2 
(UCP2) (Andrews et al., 2008), ninety percent of which co-expresses the ghrelin receptor. 
Experiments on isolated hypothalamic synaptosomes demonstrate that ghrelin increases 
oxygen consumption and reactive oxygen species (ROS) (Yamagishi et al., 2001), which 
are always associated with increased transcription and activity of UCP2 (Echtay et al., 
2002). The produced ROS are de-gradated by UCP2 (Brand et al., 2004) in order to allow 
continuous CPT1-promoted fatty acid ǃ oxidation that supports the bioenergetic needs to 
maintain firing of NPY/AgRP neurons and stimulate food intake. Compound C, an 
AMPK inhibitor, suppresses appetite stimulated by ghrelin. In UCP2-deficient mice, 
compound C fails to affect appetite. Taken together, these results suggest that lipid 
metabolism through AMPK/CPT1/UCP2 in the hypothalamic neurons is a key modulator 
for the regulation of appetite by ghrelin. 
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10.3 Ghrelin and glucose homeostasis 
It has been demonstrated that ghrelin contributes to the modulation of glucose 
homeostasis. Blocking the effect of endogenous ghrelin by D-Lys3-GHRP-6 significantly 
improves the intraperitoneal glucose tolerance test (IGTT), indicating that endogenous 
ghrelin involves in the regulation of insulin release and blood glucose homeostasis 
(Dezaki et al., 2004). Although ghrelin has been demonstrated to inhibit the activity of the 
glucosensing neurons in the dorsal vagal complex of rats (Penicaud et al., 2006; Wang et 
al., 2008), most available data validate that ghrelin modulates insulin secretion and 
sensitivity, and hepatic glucose production.  
The inhibitory effect of ghrelin on insulin secretion has been profoundly demonstrated. In 
the dissected and perfused rat pancreas, ghrelin significantly inhibits the insulin release in 
response to increasing glucose concentrations, while demonstrates no significant effect on 
basal insulin release (Egido et al., 2002). Moreover, the level of insulin released from the 
perfused pancreas is markedly increased by either blocking the GHS-R1a or immuno-
neutralizating the endogenous ghrelin. Glucose stimulated insulin release is also enhanced 
in the pancreas islets isolated from ghrelin-null mice (Dezaki et al., 2006).  
In vitro experiments show that ghrelin attenuates the inhibitory effects of insulin on 
expression of PEPCK and up-regulates the gluconeogenesis in cultured rat hepatoma cells 
(Murata et al., 2002). It also decreases the phosphorylation levels of protein kinase B (PKB) 
and glycogen synthase kinase (pGSK). All of these results provide evidences that ghrelin 
has a direct effect on hepatic glucose metabolism (Murata et al., 2002). However, GHS-R1a 
expression in the liver has not yet been demonstrated. Whether the effect of ghrelin on 
hepatic glucose metabolism is exerted via a novel ghrelin receptor subtype remains to be 
explored.  
10.4 Ghrelin and lipid metabolism 
Chronic central administration of ghrelin increases adipose deposition independently of 
food intake (Nakazato et al., 2001; Theander-Carrillo et al., 2006). Furthermore, various fat 
storage promoting enzymes such as lipoprotein lipase, acetyl-CoA carboxylase (ACC), 
fatty acid synthase(FAS), and stearoyl-CoA desaturase–1(SCD1) are markedly increased, 
while the fat oxidation rate limiting enzymes such as carnitine palmitoyl transferase–1ǂ 
(CPT1) and uncoupling proteins (UCPs) are significantly decreased (Theander-Carrillo et 
al., 2006).   
Peripheral administration of ghrelin has also been implicated on the regulation of lipid 
metabolism, with effects on liver, skeletal muscle and adipose tissue. In the liver, ghrelin 
increases lipogenic genes expression and triglyceride content, while reduces AMPK 
activity leading to lower fatty acid oxidation (Barazzoni et al., 2005). In the gastrocnemius 
muscle, ghrelin increases mitochondrial oxidative enzyme activities and reduces 
triglyceride content (Barazzoni et al., 2005). Ghrelin selectively increases peroxisome 
proliferator activated receptor Ǆ to reduce muscle fat content in skeletal muscle (Barazzoni 
et al., 2005). In adipocytes, ghrelin stimulates lipogenesis partly by the insulin-induced 
glucose uptake (Patel et al., 2006), antagonizes lipolysis induced by isoproterenol 
(Larhammar, 1996), and stimulates the proliferation and differentiation of preadipocytes 
(Kim et al., 2004). 
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10.5 Ghrelin and gastrointestinal motility 
Ghrelin is a strong gastrokinetic agent, having the motilin-like ability to stimulate motor 
activity in the gastrointestinal tract (Trudel et al., 2002). Ghrelin triggers the migrating 
motor complex in the fasted state (Fujino et al., 2003; De Winter et al., 2004; Tack et al., 
2006) and accelerates gastric emptying in the postprandial state in animals and humans 
(Asakawa et al., 2001b; De Winter et al., 2004; Binn et al., 2006; Levin et al., 2006). Ghrelin 
also accelerates the transit of the small intestine but has no effect on the colon (Trudel et 
al., 2002). The contractile response of the stomach to the intravenous administration of 
ghrelin has also been reported (Masuda et al., 2000). The prokinetic effect of ghrelin on 
motility is mediated through activation of vagal afferents because atropine or vagotomy 
blocks the contractions induced by ghrelin in these urethane-anesthetized rats (Fujino et 
al., 2003; Fukuda et al., 2004).  
Post-operative ileus is a major cause of complications and prolonged hospitalization. 
Ghrelin reverses the delay in gastric emptying in post-operative patients (Trudel et al., 
2002). Treatment with TZP-101, a synthetic ghrelin receptor agonist or RC-1139, a ghrelin 
analogue, shows promising results of acceleration of gastric emptying in rats with ileus 
induced by morphine or surgery (Poitras et al., 2005; Venkova et al., 2007). In addition, 
intravenous administration of ghrelin has been shown to accelerate gastric emptying in 
patients with diabetic, idiopathic and post-vagotomy gastroparesis (Murray et al., 2005; 
Tack et al., 2005; Binn et al., 2006). However, controversy still exists on the use of ghrelin for 
treatment of gastroparesis because that the study number of patients was small and the 
methods employed to measure gastric emptying varied from study to study (Tack et al., 
2005; Peeters, 2006). In addition, the unwanted effects of ghrelin on glucose and lipid 
metabolism should be considered. The future of ghrelin application in gastrointestinal 
motility disorder is largely dependent on our understanding of the mechanism by which 
ghrelin stimulates gastrointestingal motility (Peeters, 2006). 
10.6 Ghrelin and memory, depression and anxiety  
It was firstly demonstrated that ghrelin can increase memory retention when injected i.c.v. 
in rats (Carlini et al., 2002). Latter studies showed similar results when injected into the 
hippocampus, amygdala and dorsal raphe nucleus in rats (Carlini et al., 2004), as well as 
injected i.c.v. in chronically food-restricted mice (Carlini et al., 2008). Results from step-
down tests suggest that ghrelin might modulate specific molecular intermediates involved 
in the memory acquisition/consolidation processes (Carlini et al., 2010a). The precise 
mechanism by which ghrelin affects memory is currently unknown. It has been revealed 
that circulating ghrelin can reach the hippocampas, increase spine synapse density in CA1, 
and induce long-term potentiation (LTP), which are paralleled by enhanced spatial learning 
and memory (Diano et al., 2006). Further studies suggest that ghrelin enhances spatial 
memory by activating the PI3K signaling pathway. The NOS/NO pathway might also 
involve in the effects of ghrelin on memory consolidation. Intra-hippocampal administration 
of ghrelin increases the NOS activity dose-dependently and reduces the threshold for LTP 
generation in dentate gyrus of rats (Carlini et al., 2010b). Additional studies have showed 
that ghrelin’s effects on memory may depend on the availability of 5-HT (Carlini et al., 
2007). In contrast to the enhanced effects of ghrelin on memory in rodents, ghrelin could 
decrease memory retention in neonatal chicks (Carvajal et al., 2009) . 
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The connection between ghrelin and depression was firstly demonstrated by administrating 
ghrelin antisense DNA which induces an anti-depressant response (Kanehisa et al., 2006). 
This observation is in agreement with an increase in depression-like behavior in rats with 
central administration of ghrelin (Schanze et al., 2008). In contrast to these findings, Lutter 
and colleagues have found that increasing ghrelin levels produces antidepressant-like 
responses which may be induced by the activation of orexin neurons in the lateral 
hypothalamus (Lutter et al., 2008). It has also been revealed that chronic social defeat stress, 
a rodent model of depression, persistently increases ghrelin levels, whereas growth 
hormone secretagogue receptor (GHSR) null mice show increased deleterious effects of 
chronic defeat (Kluge et al., 2009). Clinical studies also reveal conflicting results. One study 
has reported that the levels of acylated and des-acylated ghrelin are lower in depressive 
patients before and after citalopram treatment than in the control group (Olszanecka-
Glinianowicz et al., 2010). Other studies have shown no significant difference in patients 
with major depression (Asakawa et al., 2001a; Nakashima et al., 2008; Ogaya et al., 2011). 
Despite of these controversial findings, emerging evidences suggest that ghrelin plays an 
important role in depression. Ghrelin gene polymorphism has been found to be associated 
with depression (Carlini et al., 2002). In the brain regions critical for the regulation of 
cognitive behavior, ghrelin has been reported to increase expression of glutamate receptor 
metabotropic 5 (Grm5) mRNA, GABAA-3ǂ(Gabra3) and GABAA-5ǂ receptor (Gabra5) 
subunit mRNA in the amygdala, to influence the central serotonin system (Schanze et al., 
2008), and to inhibit 5-HT release (Carlini et al., 2004). Since it has been reported that 
decreased 5-HT activity can elicit depressive like behavior (Temel et al., 2007), it is 
reasonable to believe that ghrelin might be associated with depression.  
Animal and clinical studies indicate that ghrelin is also associated with anxiety. Both central 
and peripheral administration of ghrelin induces anxiogenesis (Asakawa et al., 2001a; 
Carlini et al., 2002; Carlini et al., 2004; Carvajal et al., 2009). Ghrelin gene expression is 
increased by stresses in mice (Asakawa et al., 2001a; Hansson et al., 2011) and psychological 
stress may increase plasma ghrelin levels in humans (Rouach et al., 2007). Administration of 
anti-sense DNA for ghrelin in rats has been reported to induce an antidepressant response, 
while blockade of ghrelin decrease anxiety-like behavior (Kanehisa et al., 2006). The 
enhanced effects of ghrelin on anxiety may be mediated by corticotropin-releasing hormone 
(CRH) (Asakawa et al., 2001a) and inhibition of serotonin release (Carlini et al., 2004). In 
contrast to these observations, increasing circulating ghrelin has been reported to produce 
anxiolytic-like responses, while no longer were these anxiolytic-like behavioral responses 
observed when GHSR-null mice were calorie restricted (Lutter et al., 2008). These findings 
are consistent with a report showing low ghrelin cell activity in high-anxiety Wistar Kyoto 
rats (Kristensson et al., 2007). The reasons for the conflicting results are currently unknown 
(Andrews, 2011). 
The finding of ghrelin’s effects on brain cognitive functions will provide new therapies for 
mental disorders. 
10.7 Ghrelin and cardiovascular disease 
Numerous studies suggest that ghrelin exercises a wide array of cardiovascular activities 
including the vasodilation, improvement of myocardial function (Chang et al., 2004; Li et al., 
2006) and endothelium protection (Li et al., 2004; Tesauro et al., 2005; Rossi et al., 2007). 
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These effects may involve both peripheral and central mechanisms (Lin et al., 2004). 
Microinjection of ghrelin into the nucleus of the solitary tract significantly decreases the 
mean arterial pressure and heart rate through its action on this nucleus (Matsumura et al., 
2002; Lin et al., 2004). The direct effects of ghrelin on cardiovascular function are supported 
by the mRNA expression of both ghrelin and its receptor in the heart and aortas (Nagaya et 
al., 2001a; Gnanapavan et al., 2002). In addition, [125I-His9] ghrelin, a radio-labeled ghrelin, 
has been shown to bind to the heart and to peripheral vascular tissue (Katugampola et al., 
2001). In vitro studies demonstrated that ghrelin inhibits apoptosis of cardiomyocytes 
(Baldanzi et al., 2002), improves myocardial function during ischemia/reperfusion (Chang 
et al., 2004) and reduces infarct size (Frascarelli et al., 2003). Moreover, the radiolabeled 
ghrelin signal increases in atherosclerotic regions (Katugampola et al., 2001), suggesting that 
ghrelin receptor expression is up-regulated and ghrelin may participate in the development 
of atherosclerosis.  
Congestive heart failure (CHF) is an often-fatal condition in which the heart muscles become 
weakened and lack the strength to adequately pump blood throughout the body. In patients 
with CHF, ghrelin decreases mean arterial pressure without increasing heart rate. Chronic 
treatment with ghrelin improves left-ventricular (LV) function and exercise capacity, as well 
as attenuates the development of LV remodeling and cachexia in a rat model of chronic 
heart failure (Nagaya et al., 2001c; Nagaya et al., 2004). Treatment with synthetic GHS such 
as GHRP-6 or hexarelin improves LV function, prevents cardiac damage after ischemia, and 
attenuates fibroblast proliferation (Locatelli et al., 1999; Iwase et al., 2004; Xu et al., 2007). In 
summary, emerging data supports the role of ghrelin and its analogs as novel therapeutic 
candidates for CHF. 
10.8 Ghrelin and immunomodulation 
The expression of ghrelin and GHS-R in cells of the immune system has been detected in 
several lymphoid organs (Gnanapavan et al., 2002) and leukocyte subsets including T and B 
cells, monocytes (Dixit et al., 2004). Such widespread expression of ghrelin receptor in the 
immune system supports a role for ghrelin in the regulation of immune-related functions. 
This notion is further supported by previous studies demonstrating that ghrelin regulates 
immune cell proliferation, activation and secretion of proinflamatory cytokines (Dixit et al., 
2004; Taub, 2008). Chronic administration of a ghrelin analogue to old mice for 3 weeks has 
been demonstrated to stimulate growth, cellularity and differentiation of the thymus, and to 
increase T-cell production (Koo et al., 2001) which enhances resistance to the initiation of 
neoplasms and subsequent metastasis in animals inoculated with a transplantable 
lymphoma cell line, EL4. In addition, GHSs promotes thymic engraftment in bone marrow 
transplant of SCID mice (Koo et al., 2001). 
Upon binding with ghrelin, GHS-R elicits a potent intracellular calcium release in primary 
and cultured human T cells. In addition, GHS-R is preferentially associated with GM1+ lipid 
rafts upon cellular activation (Dixit et al., 2004). These findings suggest that GHS-R is 
actually expressed on the surface of T cells and functionally active. Activation of T cells by 
ghrelin forms the lamellipodia and remodeling of actin cytoskeleton, leading to polarization 
and directional migration (Dixit et al., 2004).  
Monocytes are important sources of proinflammatory cytokines. Initial studies show that 
ghrelin acts to inhibit the production of IL-1ǃ and IL-6 via the GHS-R because this inhibition 
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of cytokines is blunted by GHS-R antagonists (Dixit et al., 2004). All these data suggest a 
novel role for ghrelin in immune cell function as a negative regulator of inflammatory 
cytokine. 
10.9 Ghrelin and cell differentiation 
Dependent on the type of cells, ghrelin can either stimulate or inhibit the cell differentiation. 
In 3T3-L1 cell lines, over-expression of ghrelin significantly inhibits differentiation of 
adipocytes (Zhang et al., 2004) and markedly decreases mRNA and protein levels of PPARǄ, 
a marker of adipocyte differentiation. Over-expression of ghrelin in adipose tissue under the 
control of FABP4 promoter (Zhang et al., 2008) significant decreases the amount of adipose 
tissue and renders the mice resistant to diet induced obesity, which indicate that ghrelin 
may impair the development of adipose tissue (Zhang et al., 2008). 
In C2C12 cells lines, ghrelin significantly increases the differentiation of premyocytes into 
myocytes. Expression of both Myo D and myosin heavy chain protein are elevated in cells 
overexpressing ghrelin (Zhang et al., 2007), indicating the differentiation of myocyte. 
Exogenous ghrelin stimulates the proliferation of C2C12 myoblasts and promotes these 
cells to differentiate and fuse into multinucleated myotubes by activating p38 (Filigheddu 
et al., 2007).  
In both osteoblast cell lines and primary cultured osteoblasts, ghrelin stimulates an 
increase in cell proliferation and differentiation (Fukushima et al., 2005; Delhanty et al., 
2006). The expression of GHS-R1a mRNA and immunoreactivity in osteoblast cells has 
been demonstrated (Fukushima et al., 2005). The proliferative effect of ghrelin is 
suppressed by inhibitors of extracellular-signal-regulated kinase (ERK) and 
phosphoinositide-3 kinase (PI3K), indicating that ghrelin stimulates human osteoblast 
growth via MAPK/PI3K pathways. 
11. Cross talk between ghrelin and other hormones 
Normal functions of the organism rely on the precise coordination of various hormones. As 
expected, ghrelin also interacts with other hormones to exercise its biological functions.  
11.1 Growth hormone/insulin-like growth factor-1 (IGF-1) axis 
Ghrelin is known to evoke a specific, dose-dependent release of GH either in vitro or in vivo 
(Kojima et al., 1999). This effect is mediated by GHS-R because GHS-R-null mice fail to show 
the ghrelin-induced GH secretion (Sun et al., 2004). Although ablation of the ghrelin 
receptor does not reduce food intake or fat mass, GHS-R-/- mice do demonstrate modest 
reductions in body weight and exhibit biochemical alterations in IGF-1 levels (Sun et al., 
2004). IGF-1 accounts for most of the perceptible, anabolic effects of GH such as the linear 
growth and increase in skeletal muscle mass (Root, A.W. & Root, M.J., 2002). These results 
indicate that ghrelin may play a more modulatory role in GH release (Sun et al., 2004). 
Administration of growth hormone significantly decreases the serum concentration of acyl 
ghrelin (Eden Engstrom et al., 2003; Seoane et al., 2007), the total ghrelin secretion from rat 
stomach (Seoane et al., 2007), while demonstrates no effect on gastric ghrelin level (Qi et al., 
2003). These findings indicate that growth hormone exerts a negative feedback action on 
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ghrelin production and secretion. Administration of recombinant human IGF-1 in severe 
malnutrition patients elevates plasma total ghrelin concentration (Grinspoon et al., 2004). 
Because IGF-1 always inhibits growth hormone secretion, it is reasonable to assume that 
IGF-1 may induce ghrelin secretion through the reduction of growth hormone. 
11.2 Ghrelin and somatostatin  
Study has showed that ghrelin is a functional antagonist of somatostatin (Tannenbaum et 
al., 2003). This finding is in conformity with early in vitro studies of the GHSs demonstrating 
that this effect is at the level of the pituitary gland (Conley et al., 1995). However, ghrelin 
effectively stimulates GH secretion in the absence of somatostatin, indicating that its GH-
releasing activity is not dependent on inhibiting endogenous somatostatin release 
(Tannenbaum et al., 2003). 
Infusion of somatostatin or somatostatin analog octreotide significantly decreases the 
plasma acyl and total ghrelin levels (Shimada et al., 2003), indicating that somatostatin 
probably inhibits ghrelin synthesis by directly acting on the somatostatin receptor present in 
rat stomach (Silva et al., 2005). Furthermore, somatostatin null mice display an increased 
ghrelin mRNA in stomach and serum total ghrelin without any alteration in hypothalamic 
and pituitary ghrelin mRNA and serum acyl ghrelin concentration (Luque et al., 2006). Since 
serum acylated ghrelin remains unchanged in the somatostatin knockout mice, somatostatin 
may only affect the transcription and translation of ghrelin, but have no effect on its post-
translational modification.  
11.3 Ghrelin and NPY/AgRP 
Ghrelin receptor is expressed predominantly in NPY/AgRP neurons in the arcuate nucleus 
of the hypothalamus (Hahn et al., 1998; Willesen et al., 1999). The arcuate NPY/AgRP 
neurons have been shown to be essential in the control of food intake and body weight 
(Gropp et al., 2005; Luquet et al., 2005). Functional activation of these neurons by ghrelin 
increases expression of the orexigenic neuropeptides themselves, NPY and AgRP (Kamegai 
et al., 2001; Nakazato et al., 2001). NPY receptor antagonists decrease ghrelin induced 
increase in food intake (Asakawa et al., 2001b; Shintani et al., 2001; Bagnasco et al., 2003), 
while disruption of NPY and AgRP via targeted mutagenesis abolishes virtually all ghrelin-
induced effects (Chen et al., 2004; Luquet et al., 2005). All these results suggest that the 
orexigenic effect of ghrelin is fully dependent on NPY/AgRP. However, effects of ghrelin on 
appetite and body weight are not compromised in mice with selective disruption of the NPY 
gene, suggesting that AgRP may be a sufficient mediator (Tschop et al., 2002). Additional 
studies have also demonstrated that ghrelin induces more AgRP mRNA expression than 
NPY mRNA (Kamegai et al., 2001; Tschop et al., 2002). 
11.4 Ghrelin and melanocortin 
Ghrelin, either originated from blood or from local ghrelin expressing neurons, inhibits 
melanocortin signaling both directly and indirectly, resulting in an increase of food intake 
(Cowley et al., 2003). The orexigenic effect of ghrelin has been demonstrated to be 
attenuated in the Mc3r/Mc4r double knockout mice. This finding suggests that ghrelin 
stimulates energy intake partly by suppressing hypothalamic melanocortin tone. 
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Immunohistochemistry and electrophysiology studies have shown that ghrelin acts on NPY 
neurons, which synapse on and inhibit POMC neurons directly (Cowley et al., 2001) or 
activates inhibitory GABAergic interneurons innervating POMC and MC4r neurons 
(Cowley et al., 1999), thereby inhibits melanocortin signaling indirectly.  
11.5 Ghrelin and leptin  
Leptin is commonly considered as an inhibitor of ghrelin synthesis. Reciprocal relationship 
has been found between serum concentrations of ghrelin and leptin. Leptin concentration in 
obese is significantly higher than lean control, whereas ghrelin is lower (Tschop et al., 
2001b). Moreover, ghrelin mRNA increases in stomach during fasting whereas leptin and 
leptin mRNAs decrease (Zhao et al., 2008). Leptin dose-dependently inhibits ghrelin 
transcription in vitro (Zhao et al., 2008) and decreases ghrelin release from isolated rat 
stomach (Kamegai et al., 2004). Central leptin gene therapy decreases plasma leptin level, 
whereas increases ghrelin level significantly in the mouse fed with high-fat diet (Dube et al., 
2002), indicating that leptin inhibits ghrelin secretion only in peripheral tissues. Thus, 
peripheral, especially gastric leptin, might repress ghrelin expression through its receptor in 
gastric mucosa cells. 
In the CNS, 57% of neurons activated by peripheral ghrelin express the Ob-R (Traebert et al., 
2002), suggesting the co-expression of GHS-R and the Ob-R in majority of neurons. It is 
therefore proposed that ghrelin and leptin exert their opposite effect on food intake by 
acting largely on the same population of hypothalamic neurons. Ghrelin-induced increase in 
food intake in the light phase has been demonstrated to be suppressed by ICV 
administration of leptin (Nakazato et al., 2001), or pretreatment with anti-NPY 
immunoglobulin (Nakazato et al., 2001), suggesting that ghrelin and leptin may act via the 
same cellular pathway.  
Leptin has been long considered to cause satiety by depolarizing the POMC neurons, while 
hyperpolarizing NPY cells (Cowley et al., 2001). Ghrelin substantially blocks this reduction 
of feeding in rats pretreated with leptin (Nakazato et al., 2001). These results indicate that 
ghrelin may antagonize leptin action in the regulation of the NPY system. 
11.6 Ghrelin and dopamine 
When delivered directly into the VTA, ghrelin binds to the VTA neurons and produces a 
marked increase in food intake that resembles rebound feeding after fasting (Naleid et al., 
2005; Abizaid et al., 2006). GHS-R has been detected in about 50–60% VTA dopamine cells. 
In addition, VTA dopamine cells are innervated by lateral hypothalamic hypocretin ⁄ orexin 
neurones, which are also sensitive to ghrelin (Toshinai et al., 2003). These results indicate 
that ghrelin might potentially influence the release of dopamine from these cells (Abizaid et 
al., 2006; Zigman et al., 2006). This concept is supported by numerous studies in which 
extracellular dopamine content in the nucleus accumbens of rats has been shown to be 
elevated by peripheral, i.c.v. and intra-VTA injections of ghrelin (Jerlhag et al., 2006; Jerlhag 
et al., 2007; Quarta et al., 2009). Further study suggests that ghrelin increases dopamine 
release by improving the dopamine cells excitability (Abizaid et al., 2006). In the presence of 
ghrelin, dopamine cells in the VTA increase their frequency of action potentials, which 
appears to be mediated by glutamatergic neurotransmission. These changes are 
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undetectable in dopamine cells from the VTA of GHS-R knockout mice (Abizaid et al., 2006). 
As in the hypothalamus, ghrelin lowers the threshold of activation of dopamine neurons 
through mechanisms that involve remodeling the ratio of excitatory versus inhibitory inputs 
onto these cells (Abizaid et al., 2006).  
Peripheral injections of ghrelin increase dopamine turnover in the ventral striatum of mice 
and rats (Abizaid et al., 2006). Considering that the VTA is protected by the blood–brain 
barrier and less permeable than the arcuate nuclei to blood-borne substances, ghrelin might 
be transported into VTA through a saturable mechanism remained to be fully determined 
(Banks et al., 2002). Another possibility is the indirect effect of ghrelin on afferent neurons 
which innervate the VTA such as lateral hypothalamic neurons and laterodorsal tegmental 
nucleus (Guan et al., 1997; Geisler & Zahm, 2005). 
11.7 Ghrelin and insulin  
In human pancreatic islets, ghrelin receptor immunoreactivity partially overlaps with 
insulin-positive ǃ-cells (Granata et al., 2007), indicating that human ǃ-cells might also be 
responsive to ghrelin stimulation. In cultured islet cells, acyl-ghrelin suppresses both basal 
insulin secretion (Dezaki et al., 2004) and glucose-induced insulin release (Dezaki et al., 
2006). The level of insulin released from the perfused pancreas is significantly increased by 
either blocking the GHS-R1a or immunoneutralizating the endogenous ghrelin. 
Furthermore, glucose-induced insulin release is greater in islets isolated from ghrelin-null 
mice than wild type littermates. All these data suggest that ghrelin regulates insulin 
secretion from the islet cells. The molecular mechanism by which ghrelin suppresses 
glucose-induced insulin release has been reported to be the attenuation of Ca2+ signaling in 
ǃ-cells via Gǂi2 and Kv channel (Dezaki et al., 2007). 
Gastric artery perfusion of insulin significantly inhibits ghrelin release from isolated 
stomach tissue in rats (Kamegai et al., 2004). Central administration of insulin reduces 
serum total ghrelin concentration (Ueno et al., 2006), while maintaining euglycemia (Saad et 
al., 2002; Flanagan et al., 2003). Several clinical observations in humans also indicate that 
insulin may inhibit ghrelin secretion. 
11.8 Ghrelin and glucagon 
Both ghrelin and GHS-R1a have been identified in either human or rat pancreatic islets ǂ 
cells (Date et al., 2002). Ghrelin induces significant increase in glucagon secretion from the 
pancreas of diabetic rats rather than in normal rats (Adeghate & Parvez, 2002). A possible 
reason for this difference is that signal transduction involving the calcium pathway is 
impaired in diabetic rat pancreas.  
Glucagon may stimulate the gene transcription of ghrelin as well. Glucagon might elevate 
the activity of ghrelin gene promoter by the mediation of the second messenger cAMP (Wei 
et al., 2005). Several studies suggest that glucagon may contribute to the pre-prandial surge 
of ghrelin. Glucagon receptor is present in endocrine cells in gastric mucosa (Katayama et 
al., 2007). Glucagon concentration increases during fasting, and plasma acyl ghrelin 
concentration rises after administration of glucagon in rats. In addition, ghrelin released 
from the rat stomach is augmented by glucagon (Kamegai et al., 2004).  
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11.9 Ghrelin and estrogen 
Numerous studies report that estrogen up-regulates ghrelin level. The effects of estrogen to 
stimulate food intake and growth hormone secretion might therefore be partially mediated 
through ghrelin. Plasma total ghrelin concentration in female patients with anorexia nervosa 
is significantly elevated (Grinspoon et al., 2004), while ghrelin mRNA level rises 
dramatically in cultured stomach cells (Sakata et al., 2006) after estrogen administration. 
Discrepant results on the effect of estrogen on ghrelin have been reported. Precise 
mechanism for the discrepancy remains unknown, but may relate to the distinction of age 
(Matsubara et al., 2004), physiological status (Chu et al., 2006) and variation in methods 
used for estrogen application (Kellokoski et al., 2005; Chu et al., 2006). Estrogen replacement 
therapy in post-menopausal women has been reported to induce increase (Kellokoski et al., 
2005; Lambrinoudaki et al., 2008), no significant change, or even decreases (Chu et al., 2006) 
in serum total and acyl ghrelin secretion. In female rats, ovariectomy induces a transient 
augment in plasma acyl ghrelin, ghrelin expressing cells and ghrelin mRNA in stomach 
(Matsubara et al., 2004).  
12. Conclusion 
Since its discovery in 1999, ghrelin has attracted a tremendous interest from both academy 
and industry. It has become one of the most extensively studied fields. This is due to its 
highly conserved sequence between species, its unique molecular structure, and the 
ubiquity of ghrelin and receptors which implicates its important physiological function 
during the development. The multiplicity of physiological functions of ghrelin are revealing 
gradually. Current evidences show that ghrelin affects GH release, food intake, energy and 
glucose homeostasis, gastrointestinal, cardiovascular and immune functions, cell 
proliferation and differentiation, and cognitive behavior. Ghrelin is therefore a critical 
hormone linking the gastrointestinal activities with organism functions. 
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